Search
Clavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approved[A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910] … [T665] Clavulanic acid is derived from the organism Streptomyces clavuligerus.
Mixtures: CROXILEX 1.2G IV ENJEKSİYON İÇİN TOZ İÇEREN FLAKON, Amoklavin 1000 mg/200 mg IV Enjeksiyonluk/İnfüzyonluk Çözelti Hazırlamak İçin Toz ve ÇözücüRusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigational[A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762] … [T521] Desogestrel is now produced semi-synthetically from naturally occurred plant steroids.[F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Synonyms: 13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-olTozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386,L15007] Comirnaty is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15002] The modRNA is formulated in lipid nanoparticles for administration via intramuscular injection in two doses, three weeks apart.
rdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalDeoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalIt must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.